XNAS
LITS
Market cap6mUSD
Jul 09, Last price
0.99USD
1D
1.65%
1Q
-14.40%
Jan 2017
-96.55%
IPO
-99.99%
Name
MEI Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.93%
Rev. gr., 5y
67.75%
Revenues
0k
-100.00%
Net income
-16m
L
CFO
-21m
L-58.70%
Dividend
Nov 16, 20231.75 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an intravenously administered small molecule. This therapy is designed to inhibit mitochondrial oxidative phosphorylation and aims to combat specific cancer types, including human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and other solid tumors. In addition to its drug development activities, Lite Strategy also engages in the management of digital asset treasuries. The organization, which was formerly known as MEI Pharma, Inc., is slated to officially adopt the name Lite Strategy, Inc. in September 2025. Established in 2000, the company maintains its headquarters in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||